Payment overview · 2025
General Payments
$266.18
18 reported records · 5 companies
Healthcare provider profile · identity verified
Frank C Wade, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MAGEE, MS · NPI 1619934940
Verified facts
What the public records show
CMS Open Payments records show Frank C Wade, M.D. received $266.18 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 52.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $139.20 | 52.3% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.77 | 29.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.74 | 8.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.28 | 5.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.19 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $266.18 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $84.63 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $84.63 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.57 | 5 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.92 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.85 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 155 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
155 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 590 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 503 | 151 |
| Gabapentin | Gabapentin | 394 | 97 |
| Omeprazole | Omeprazole | 359 | 92 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 272 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 266 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 254 | 68 |
| Furosemide | Furosemide | 225 | 76 |
| Meloxicam | Meloxicam | 214 | 58 |
| Lisinopril | Lisinopril | 209 | 51 |
| Metformin Hcl | Metformin Hcl | 209 | 67 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 204 | 76 |
| Duloxetine Hcl | Duloxetine Hcl | 198 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 191 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 187 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 181 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 47 |
| Losartan Potassium | Losartan Potassium | 168 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 40 |
| Potassium Chloride | Potassium Chloride | 165 | 50 |
| Jardiance | Empagliflozin | 155 | 31 |
| Eliquis | Apixaban | 151 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 47 |
| Trazodone Hcl | Trazodone Hcl | 149 | 45 |
| Carvedilol | Carvedilol | 146 | 40 |
| Tramadol Hcl | Tramadol Hcl | 144 | 30 |
| Metformin Hcl Er | Metformin Hcl | 132 | 33 |
| Ozempic | Semaglutide | 132 | 25 |
| Sertraline Hcl | Sertraline Hcl | 111 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 110 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 34 |
| Famotidine | Famotidine | 107 | 22 |
| Azithromycin | Azithromycin | 105 | 82 |
| Montelukast Sodium | Montelukast Sodium | 105 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 101 | 61 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 24 |
| Prednisone | Prednisone | 100 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 18 |
| Ezetimibe | Ezetimibe | 94 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 90 | 27 |
| Alprazolam | Alprazolam | 83 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 82 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 78 | 50 |
| Valsartan | Valsartan | 78 | 16 |
| Allopurinol | Allopurinol | 75 | 26 |
| Buspirone Hcl | Buspirone Hcl | 70 | 20 |
| Farxiga | Dapagliflozin Propanediol | 68 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 67 | 31 |
| Methocarbamol | Methocarbamol | 67 | 36 |
| Bupropion Xl | Bupropion Hcl | 65 | 16 |
| Simvastatin | Simvastatin | 64 | 18 |
| Fluconazole | Fluconazole | 63 | 27 |
| Warfarin Sodium | Warfarin Sodium | 63 | 13 |
| Diazepam | Diazepam | 62 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 15 |
| Glimepiride | Glimepiride | 61 | 19 |
| Primidone | Primidone | 61 | 15 |
| Synthroid | Levothyroxine Sodium | 60 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 36 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 13 |
| Spironolactone | Spironolactone | 53 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 52 | 11 |
| Temazepam | Temazepam | 52 | 12 |
| Bumetanide | Bumetanide | 51 | 11 |
| Donepezil Hcl | Donepezil Hcl | 51 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 11 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 17 |
| Amoxicillin | Amoxicillin | 44 | 29 |
| Topiramate | Topiramate | 44 | 14 |
| Nifedipine Er | Nifedipine | 43 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 42 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 40 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 28 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Sucralfate | Sucralfate | 39 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 16 |
| Linzess | Linaclotide | 38 | 12 |
| Clonidine Hcl | Clonidine Hcl | 37 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 20 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | 11 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Vraylar | Cariprazine Hcl | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 22 |
| Glipizide | Glipizide | 30 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 30 | 20 |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 13 |
| Mupirocin | Mupirocin | 23 | 15 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | 13 |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 15 |
| Estradiol | Estradiol | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nystatin | Nystatin | 16 | 15 |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $266.18 · 18 records | ABBVIE INC. | Auvelity, CAPLYTA, JARDIANCE, OFEV, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error